Literature DB >> 8428898

Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis.

E A Workman1, D D Short.   

Abstract

BACKGROUND: Our investigation involved a quantitative literature review technique known as meta-analysis to compare the efficacy of three newer antidepressants and imipramine.
METHOD: We examined seven major journals in psychiatry from 1980 through 1990, inclusive, and selected those investigations of imipramine, trazodone, bupropion, and fluoxetine that met our minimal criteria for interpretability. These criteria included: (1) the presence of a placebo control, (2) double-blind status, (3) the use of the Hamilton Rating Scale for Depression as a dependent variable measure, (4) the use of nongeriatric adults with a diagnosis of major depression by DSM or RDC standards, and (5) the presence of reported means and standard deviations in the investigation, or sufficient data that allowed such to be computed. Each study of four antidepressants was analyzed for an effect size of the drug investigated. The effect size allows for a determination of the efficacy of a particular drug as compared with placebo, measured in standard deviation units.
RESULTS: The data indicated that all four agents are effective as compared with placebo. Furthermore, there is no evidence that the newer heterocyclic agents are less effective than imipramine, as an ANOVA showed no statistically significant difference between the effect sizes of the four antidepressants.
CONCLUSION: These data are discussed in terms of characteristics of the various investigations and the need for further research comparing the efficacy of psychopharmacologic agents.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8428898

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

Review 1.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

2.  Assessment of health-related quality of life, mental health status and psychological distress based on the type of pharmacotherapy used among patients with depression.

Authors:  Drishti Shah; Varun Vaidya; Amit Patel; Mary Borovicka; Monica-Holiday Goodman
Journal:  Qual Life Res       Date:  2016-09-26       Impact factor: 4.147

3.  General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11       Impact factor: 5.270

Review 4.  The economics of selective serotonin reuptake inhibitors in depression: a critical review.

Authors:  L Frank; D A Revicki; S V Sorensen; Y C Shih
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

5.  Relative mortality from overdose of antidepressants.

Authors:  J A Henry; C A Alexander; E K Sener
Journal:  BMJ       Date:  1995-01-28

6.  Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan J Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-15       Impact factor: 5.270

Review 7.  Epidemiology and relative toxicity of antidepressant drugs in overdose.

Authors:  J A Henry
Journal:  Drug Saf       Date:  1997-06       Impact factor: 5.606

8.  Effect of bupropion on nicotine self-administration in rats.

Authors:  Anthony S Rauhut; Nicole Neugebauer; Linda P Dwoskin; Michael T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2003-06-17       Impact factor: 4.530

9.  Mood Disorders in Neurologic Illness.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-03       Impact factor: 3.972

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.